ipc298 cell line Search Results


cancer cell lines  (ATCC)
99
ATCC cancer cell lines
Cancer Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ipc298+cell+line/us12479842-2347-105-132?v=ATCC
Average 99 stars, based on 1 article reviews
cancer cell lines - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier
cell culture cell lines  (ATCC)
96
ATCC cell culture cell lines
Cell Culture Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ipc298+cell+line/10__1074_slash_jbc__m600883200-52-0-18?v=ATCC
Average 96 stars, based on 1 article reviews
cell culture cell lines - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier
ipc 298 human melanoma cell lines  (DSMZ)
93
DSMZ ipc 298 human melanoma cell lines
Ipc 298 Human Melanoma Cell Lines, supplied by DSMZ, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ipc298+cell+line/med_rxiv__2022__06__20__22276663-77-5-15?v=DSMZ
Average 93 stars, based on 1 article reviews
ipc 298 human melanoma cell lines - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
cell lines  (ATCC)
99
ATCC cell lines
Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ipc298+cell+line/pmc08888590-318-1-14?v=ATCC
Average 99 stars, based on 1 article reviews
cell lines - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier
skmel28 cell line  (Array BioPharma)
90
Array BioPharma skmel28 cell line
(A) Experimental setup for cell line xenograft studies of mice + binimetinib or encorafinib. X-axis describes days of therapy and drug treatment (M=MEKi, binimetinib and B=BRAFi, encorafinib). (B) Volcano plot, average fold change in pMHC expression with binimetinib treatment (n=3 biological replicates for DMSO and MEKi treated cells) versus significance (mean-adjusted p value, unpaired two-sided t test) for <t>IPC298</t> CLX. (C) Violin plot of distribution of fold changes in presentation of pMHCs following MEK inhibition (M, binimetinib), BRAF inhibition (B, encorafinib) or both (B/M). Solid line represents median, dotted lines define the first and third quartiles. (D) TAA enrichment significance values for each analysis. Black dotted line represents p≥0.05, grey = p≥0.01. (E) Changes in pMHC expression for select melanoma differentiation antigens. Errors bars represent standard deviation when >1 peptide from each source protein was identified.
Skmel28 Cell Line, supplied by Array BioPharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ipc298+cell+line/bio_rxiv__2022__01__10__475285-173-4-18?v=Array+BioPharma
Average 90 stars, based on 1 article reviews
skmel28 cell line - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
ipc298 cell line  (Array BioPharma)
90
Array BioPharma ipc298 cell line
(A) Experimental setup for cell line xenograft studies of mice + binimetinib or encorafinib. X-axis describes days of therapy and drug treatment (M=MEKi, binimetinib and B=BRAFi, encorafinib). (B) Volcano plot, average fold change in pMHC expression with binimetinib treatment (n=3 biological replicates for DMSO and MEKi treated cells) versus significance (mean-adjusted p value, unpaired two-sided t test) for <t>IPC298</t> CLX. (C) Violin plot of distribution of fold changes in presentation of pMHCs following MEK inhibition (M, binimetinib), BRAF inhibition (B, encorafinib) or both (B/M). Solid line represents median, dotted lines define the first and third quartiles. (D) TAA enrichment significance values for each analysis. Black dotted line represents p≥0.05, grey = p≥0.01. (E) Changes in pMHC expression for select melanoma differentiation antigens. Errors bars represent standard deviation when >1 peptide from each source protein was identified.
Ipc298 Cell Line, supplied by Array BioPharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ipc298+cell+line/pmc09894220-150-4-15?v=Array+BioPharma
Average 90 stars, based on 1 article reviews
ipc298 cell line - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
belvarafenib-resistant ipc-298 cell lines  (Genentech inc)
90
Genentech inc belvarafenib-resistant ipc-298 cell lines
(A) Experimental setup for cell line xenograft studies of mice + binimetinib or encorafinib. X-axis describes days of therapy and drug treatment (M=MEKi, binimetinib and B=BRAFi, encorafinib). (B) Volcano plot, average fold change in pMHC expression with binimetinib treatment (n=3 biological replicates for DMSO and MEKi treated cells) versus significance (mean-adjusted p value, unpaired two-sided t test) for <t>IPC298</t> CLX. (C) Violin plot of distribution of fold changes in presentation of pMHCs following MEK inhibition (M, binimetinib), BRAF inhibition (B, encorafinib) or both (B/M). Solid line represents median, dotted lines define the first and third quartiles. (D) TAA enrichment significance values for each analysis. Black dotted line represents p≥0.05, grey = p≥0.01. (E) Changes in pMHC expression for select melanoma differentiation antigens. Errors bars represent standard deviation when >1 peptide from each source protein was identified.
Belvarafenib Resistant Ipc 298 Cell Lines, supplied by Genentech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ipc298+cell+line/pm33953400-368-0-26?v=Genentech+inc
Average 90 stars, based on 1 article reviews
belvarafenib-resistant ipc-298 cell lines - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
invasion human malignant melanoma cell lines  (ATCC)
99
ATCC invasion human malignant melanoma cell lines
(A) Experimental setup for cell line xenograft studies of mice + binimetinib or encorafinib. X-axis describes days of therapy and drug treatment (M=MEKi, binimetinib and B=BRAFi, encorafinib). (B) Volcano plot, average fold change in pMHC expression with binimetinib treatment (n=3 biological replicates for DMSO and MEKi treated cells) versus significance (mean-adjusted p value, unpaired two-sided t test) for <t>IPC298</t> CLX. (C) Violin plot of distribution of fold changes in presentation of pMHCs following MEK inhibition (M, binimetinib), BRAF inhibition (B, encorafinib) or both (B/M). Solid line represents median, dotted lines define the first and third quartiles. (D) TAA enrichment significance values for each analysis. Black dotted line represents p≥0.05, grey = p≥0.01. (E) Changes in pMHC expression for select melanoma differentiation antigens. Errors bars represent standard deviation when >1 peptide from each source protein was identified.
Invasion Human Malignant Melanoma Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ipc298+cell+line/pm26446958-105-8-21?v=ATCC
Average 99 stars, based on 1 article reviews
invasion human malignant melanoma cell lines - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier

Image Search Results


(A) Experimental setup for cell line xenograft studies of mice + binimetinib or encorafinib. X-axis describes days of therapy and drug treatment (M=MEKi, binimetinib and B=BRAFi, encorafinib). (B) Volcano plot, average fold change in pMHC expression with binimetinib treatment (n=3 biological replicates for DMSO and MEKi treated cells) versus significance (mean-adjusted p value, unpaired two-sided t test) for IPC298 CLX. (C) Violin plot of distribution of fold changes in presentation of pMHCs following MEK inhibition (M, binimetinib), BRAF inhibition (B, encorafinib) or both (B/M). Solid line represents median, dotted lines define the first and third quartiles. (D) TAA enrichment significance values for each analysis. Black dotted line represents p≥0.05, grey = p≥0.01. (E) Changes in pMHC expression for select melanoma differentiation antigens. Errors bars represent standard deviation when >1 peptide from each source protein was identified.

Journal: bioRxiv

Article Title: MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas

doi: 10.1101/2022.01.10.475285

Figure Lengend Snippet: (A) Experimental setup for cell line xenograft studies of mice + binimetinib or encorafinib. X-axis describes days of therapy and drug treatment (M=MEKi, binimetinib and B=BRAFi, encorafinib). (B) Volcano plot, average fold change in pMHC expression with binimetinib treatment (n=3 biological replicates for DMSO and MEKi treated cells) versus significance (mean-adjusted p value, unpaired two-sided t test) for IPC298 CLX. (C) Violin plot of distribution of fold changes in presentation of pMHCs following MEK inhibition (M, binimetinib), BRAF inhibition (B, encorafinib) or both (B/M). Solid line represents median, dotted lines define the first and third quartiles. (D) TAA enrichment significance values for each analysis. Black dotted line represents p≥0.05, grey = p≥0.01. (E) Changes in pMHC expression for select melanoma differentiation antigens. Errors bars represent standard deviation when >1 peptide from each source protein was identified.

Article Snippet: SKMEL5, SKMEL28, SKMEL2, and IPC298 cell lines were used for cell line xenograft (CLX) analyses in collaboration with Array Biopharma.

Techniques: Expressing, Inhibition, Standard Deviation